2032年までのトファシチニブの世界市場機会と戦略

Tofacitinib Global Market Opportunities And Strategies To 2032

ビジネスリサーチ社の2032年までのトファシチニブ世界市場のビジネスチャンスと戦略では、戦略家、マーケティング担当者、上級管理職がCOVID-19の閉鎖から脱却する世界のトファシチニブ市場を評価するために必要... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Business Research Company　(TBRC) ザ・ビジネスリサーチカンパニー	2024年1月4日	US$5,000 シングルユーザライセンスライセンス・価格情報注文方法はこちら	244	英語

サマリー

ビジネスリサーチ社の2032年までのトファシチニブ世界市場のビジネスチャンスと戦略では、戦略家、マーケティング担当者、上級管理職がCOVID-19の閉鎖から脱却する世界のトファシチニブ市場を評価するために必要な重要な情報を提供しています。

購入の理由
- 12地域をカバーするこの市場に関する最も包括的なレポートにより、真のグローバルな視点を得ることができます。
- 市場がコロナウイルスからどのような影響を受けているのか、また、ウイルスの影響が和らぐにつれて市場がどのように浮上し、成長する可能性があるのかを理解する。
- 現地のデータと分析に基づき、地域別および国別の戦略を策定します。
- 投資の対象となる成長セグメントを特定する。
- 予測データと市場を形成するドライバーとトレンドを活用し、競合他社を凌駕する。
- 最新の市場調査結果に基づいて顧客を理解する。
- 主要な競合他社とのパフォーマンスの比較
- 主要データセット間の関係を活用し、優れた戦略を立てる。
- 信頼性の高い高品質なデータと分析により、社内外のプレゼンテーションをサポートします。

説明
トファシチニブの最大かつ最速の成長市場はどこか？経済全体、人口動態、他の類似市場との関連は？今後の市場を形成する勢力は何か？ビジネスリサーチ社のトファシチニブ世界市場レポートでは、これらすべての疑問やその他多くの疑問にお答えします。
当レポートでは、市場の特徴、規模と成長、セグメンテーション、地域別および国別内訳、競合情勢、市場シェア、市場の動向と戦略を網羅しています。地域別に市場の過去および予測成長を追跡しています。トファシチニブ市場全体の中で同市場を位置づけ、他市場との比較も行っています。

本レポートは以下の章をカバーしています。
- 序論と市場の特徴
薬剤クラス別、投与強さ別、適応症別、流通チャネル別のセグメントについて、定義と解説を交えて簡単に紹介しています。
- 主要動向
世界市場を形成している主なトレンドにハイライトを当てています。また、今後の市場動向についても取り上げます。
- マクロ経済シナリオ
ロシア・ウクライナ戦争の影響、COVID-19パンデミックの影響、インフレ上昇が世界市場および地域市場に与える影響について分析し、トファシチニブ市場におけるビジネスに戦略的洞察を提供します。
- 世界市場の規模と成長
世界の過去（2017年～2022年）および予測（2022年～2027年、2032F）市場価値、ならびに過去および予測期間における市場成長を支え、制御する推進要因と阻害要因。
- 地域別および国別分析
地域別・国別の過去（2017～2022年）および予測（2022～2027年、2032F）市場価値と成長、市場シェア比較
- 市場セグメンテーション
市場における薬剤クラス別、投与強さ別、適応症別、流通チャネル別の市場価値（2017-2022年）（2022-2027年、2032F）と各セグメント別の分析を収録。地域市場別の過去（2017-2022年）、予測（2022-2027年）、（2027-2032年）市場価値と成長率、市場シェア比較を掲載。
- 地域別市場規模および成長率
地域別市場規模（2022年）、過去（2017-2022年）および予測（2022-2027,2032F）市場価値、地域内各国の成長率と市場シェア比較。アジア太平洋、西欧、東欧、北米、南米、中東、アフリカの全地域と各地域内の主要国に関する情報を掲載しています。
- 競争環境
市場の競争状況、推定市場占有率、主要企業の会社プロファイルの詳細を掲載しています。
- 主要なM&A
市場における最近のM&Aに関する情報を掲載しています。近年の市場を形成したM&Aに関する主要な財務情報を掲載しています。
- 市場機会と戦略
調査結果に基づく市場機会と戦略について、国やセグメントごとの成長機会やそれらの市場で取るべき戦略に関する情報を交えて解説しています。
- 結論と提言
製品・サービスの提供地域拡大、マーケティング戦略、ターゲット層など、トファシチニブ・プロバイダーへの提言を掲載しています。
- 付録
このセクションには、本レポートで使用したNAICSコード、略語、通貨コードの詳細が含まれています。

対象範囲
対象市場
1) 薬剤クラス別薬剤クラス別：抗リウマチ薬；ヤヌスキナーゼ阻害薬；免疫抑制薬
2) 投与強度別：5mg、10mg、11mg、22mg
3) 効能・効果別潰瘍性大腸炎；関節リウマチ；乾癬；その他の適応症
4) 販売チャネル別病院薬局；小売薬局；オンライン薬局

言及された企業ファイザー; ビーコン・ファーマシューティカルズ PLC; ファーマサイエンス; Qilu Pharmaceutical Co, Ltd; デルタ・ファーマ; ドラッグ・インターナショナル; グローブ・グループ

国名中国、オーストラリア、インド、インドネシア、日本、韓国、アメリカ、ブラジル、フランス、ドイツ、イギリス、ロシア

地域アジア太平洋; 西ヨーロッパ; 東ヨーロッパ; 北アメリカ; 南アメリカ; 中東; アフリカ

時系列：過去5年間および過去10年間の予測。

データ市場規模と成長率の関連市場に対する比率、GDP比率、一人当たり支出、トファシチニブ指標の比較。

データ区分：国別・地域別の過去データと予測データ、競合他社の市場シェア、市場セグメント。

ソーシングと参照：本レポート中のデータおよび分析は、エンドノートを使用しています。

ページTOPに戻る

1 Executive Summary
1.1 Tofacitinib – Market Attractiveness And Macro economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Tofacitinib Market Definition And Segmentations
6.4 Market Segmentation By Drug Class
6.4.1 Antirheumatic
6.4.2 Janus Kinase Inhibitor
6.4.3 Immunosuppressant
6.5 Market Segmentation By Dosage Strength
6.5.1 5mg
6.5.2 10mg
6.5.3 11mg
6.5.4 22mg
6.6 Market Segmentation By Indication
6.6.1 Ulcerative Colitis
6.6.2 Rheumatoid Arthritis
6.6.3 Psoriasis
6.6.4 Other Indications
6.7 Market Segmentation By Distribution Channel
6.7.1 Hospital Pharmacy
6.7.2 Retail Pharmacy
6.7.3 Online Pharmacy
7 Major Market Trends
7.1 Development Of Advanced Products Such As Tofacitinib Ointment To Treat Rheumatoid Arthritis
7.2 Focus on Getting Approval Of Tofacitinib In New Geographies
7.3 Increase In Generic Drug Launches To Provide Affordable Treatment
8 Tofacitinib Market - Macro Economic Scenario
8.1 COVID-19 Impact On The Tofacitinib Market
8.2 Impact Of The War In Ukraine On The Tofacitinib Market
8.3 Impact Of High Inflation On The Tofacitinib Market
9 Global Market Size and Growth
9.1 Market Size
9.2 Historic Market Growth, 2017 – 2022, Value ($ Million)
9.3 Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
9.4 Market Drivers
9.5 Market Restraints
10 Global Tofacitinib Market Segmentation
10.1 Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
10.2 Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
10.3 Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
10.4 Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
11 Tofacitinib Market, Regional and Country Analysis
11.1 Global Tofacitinib Market, By Region, Historic and Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
11.2 Global Tofacitinib Market, By Country, Historic and Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12 Asia-Pacific Market
12.1 Summary
12.1.1 Market Overview
12.1.2 Region Information
12.1.3 Market Information
12.1.4 Background Information
12.1.5 Government Initiatives
12.1.6 Regulations
12.1.7 Regulatory Bodies
12.1.8 Major Associations
12.1.9 Taxes Levied
12.1.10 Corporate Tax Structure
12.1.11 Investments
12.1.12 Major Companies
12.2 Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.3 Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.4 Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.5 Asia-Pacific Tofacitinib Market: Country Analysis
12.6 China Market
12.7 Summary
12.7.1 Market Overview
12.7.2 Country Information
12.7.3 Market Information
12.7.4 Background Information
12.7.5 Government Initiatives
12.7.6 Regulations
12.7.7 Regulatory Bodies
12.7.8 Major Associations
12.7.9 Taxes Levied
12.7.10 Corporate Tax Structure
12.7.11 Investments
12.7.12 Major Companies
12.8 China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.9 China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.10 China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.11 India Market
12.12 India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.13 India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.14 India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.15 Japan Market
12.16 Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.17 Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.18 Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.19 Australia Market
12.20 Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.21 Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.22 Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.23 Indonesia Market
12.24 Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.25 Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.26 Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.27 South Korea Market
12.28 South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.29 South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.3 South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13 Western Europe Market
13.1 Summary
13.1.1 Market Overview
13.1.2 Region Information
13.1.3 Market Information
13.1.4 Background Information
13.1.5 Government Initiatives
13.1.6 Regulations
13.1.7 Regulatory Bodies
13.1.8 Major Associations
13.1.9 Taxes Levied
13.1.10 Corporate tax structure
13.1.11 Investments
13.1.12 Major Companies
13.2 Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.3 Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.4 Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.5 Western Europe Tofacitinib Market: Country Analysis
13.6 UK Market
13.7 UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.8 UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.9 UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.10 Germany Market
13.11 Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.12 Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.13 Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.14 France Market
13.15 France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.16 France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.17 France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14 Eastern Europe Market
14.1 Summary
14.1.1 Market Overview
14.1.2 Region Information
14.1.3 Market Information
14.1.4 Background Information
14.1.5 Government Initiatives
14.1.6 Regulations
14.1.7 Regulatory Bodies
14.1.8 Major Associations
14.1.9 Taxes Levied
14.1.10 Corporate Tax Structure
14.1.11 Investments
14.1.12 Major Companies
14.2 Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.3 Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.4 Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.5 Eastern Europe Tofacitinib Market: Country Analysis
14.6 Russia Market
14.7 Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.8 Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.9 Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15 North America Market
15.1 Summary
15.1.1 Market Overview
15.1.2 Region Information
15.1.3 Market Information
15.1.4 Background Information
15.1.5 Government Initiatives
15.1.6 Regulations
15.1.7 Regulatory Bodies
15.1.8 Major Associations
15.1.9 Taxes Levied
15.1.10 Corporate Tax Structure
15.1.11 Investments
15.1.12 Major Companies
15.2 North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.3 North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.4 North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.5 North America Tofacitinib Market: Country Analysis
15.6 USA Market
15.7 Summary
15.7.1 Market Overview
15.7.2 Country Information
15.7.3 Market Information
15.7.4 Background Information
15.7.5 Government Initiatives
15.7.6 Regulations
15.7.7 Regulatory Bodies
15.7.8 Major Associations
15.7.9 Taxes Levied
15.7.10 Corporate Tax Structure
15.7.11 Investments
15.7.12 Major Companies
15.8 USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.9 USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.10 USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16 South America Market
16.1 Summary
16.1.1 Market Overview
16.1.2 Region Information
16.1.3 Market Information
16.1.4 Background Information
16.1.5 Government Initiatives
16.1.6 Regulations
16.1.7 Regulatory Bodies
16.1.8 Major Associations
16.1.9 Taxes Levied
16.1.10 Corporate Tax Structure
16.1.11 Investments
16.1.12 Major Companies
16.2 South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.3 South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.4 South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.5 South America Tofacitinib Market: Country Analysis
16.6 Brazil Market
16.7 Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.8 Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.9 Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
17 Middle East Market
17.1 Summary
17.1.1 Market Overview
17.1.2 Region Information
17.1.3 Market Information
17.1.4 Background Information
17.1.5 Government Initiatives
17.1.6 Regulations
17.1.7 Regulatory Bodies
17.1.8 Major Associations
17.1.9 Taxes Levied
17.1.10 Corporate Tax Structure
17.1.11 Investments
17.1.12 Major Companies
17.2 Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
17.3 Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
17.4 Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
18 Africa Market
18.1 Summary
18.1.1 Market Overview
18.1.2 Region Information
18.1.3 Market Information
18.1.4 Background Information
18.1.5 Government Initiatives
18.1.6 Regulations
18.1.7 Regulatory Bodies
18.1.8 Major Associations
18.1.9 Taxes Levied
18.1.10 Corporate Tax Structure
18.1.11 Major Companies
18.2 Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
18.3 Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
18.4 Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
19 Competitive Landscape and Company Profiles
19.1 Company Profiles
19.2 Pfizer Inc
19.2.1 Company Overview
19.2.2 Products And Services
19.2.3 Business Strategy
19.2.4 Financial Overview
19.3 Beacon Pharmaceuticals PLC
19.3.1 Company Overview
19.3.2 Products And Services
19.3.3 Business Strategy
19.3.4 Financial Overview
19.4 Pharmascience Inc.
19.4.1 Company Overview
19.4.2 Products And Services
19.4.3 Business Strategy
19.4.4 Financial Overview
19.5 Qilu Pharmaceutical Co., Ltd
19.5.1 Company Overview
19.5.2 Products And Services
19.5.3 Business Strategy
19.5.4 Financial Overview
19.6 Delta Pharma Limited
19.6.1 Company Overview
19.6.2 Products And Services
19.6.3 Financial Overview
20 Key Mergers And Acquisitions
20.1 Sun Pharma Acquired Concert Pharmaceuticals
20.2 GSK Acquired Sierra Oncology
20.3 Pfizer Acquired Arena Pharmaceuticals
21 Opportunities And Strategies
21.1 Global Tofacitinib Market In 2027 – Countries Offering Most New Opportunities
21.2 Global Tofacitinib Market In 2027 – Segments Offering Most New Opportunities
21.3 Global Tofacitinib Market In 2027 – Growth Strategies
21.3.1 Market Trend Based Strategies
21.3.2 Competitor Strategies
22 Tofacitinib Market, Conclusions And Recommendations
22.1 Conclusions
22.2 Recommendations
22.2.1 Product
22.2.2 Place
22.2.3 Price
22.2.4 Promotion
22.2.5 People
23 Appendix
23.1 Geographies Covered
23.2 Market Data Sources
23.3 Research Methodology
23.4 Currencies
23.5 The Business Research Company
23.6 Copyright and Disclaimer

2 Products And Services
19.3.3 Business Strategy
19.3.4 Financial Overview
19.4 Pharmascience Inc.
19.4.1 Company Overview
19.4.2 Products And Services
19.4.3 Business Strategy
19.4.4 Financial Overview
19.5 Qilu Pharmaceutical Co., Ltd
19.5.1 Company Overview
19.5.2 Products And Services
19.5.3 Business Strategy
19.5.4 Financial Overview
19.6 Delta Pharma Limited
19.6.1 Company Overview
19.6.2 Products And Services
19.6.3 Financial Overview
20 Key Mergers And Acquisitions
20.1 Sun Pharma Acquired Concert Pharmaceuticals
20.2 GSK Acquired Sierra Oncology
20.3 Pfizer Acquired Arena Pharmaceuticals
21 Opportunities And Strategies
21.1 Global Tofacitinib Market In 2027 – Countries Offering Most New Opportunities
21.2 Global Tofacitinib Market In 2027 – Segments Offering Most New Opportunities
21.3 Global Tofacitinib Market In 2027 – Growth Strategies
21.3.1 Market Trend Based Strategies
21.3.2 Competitor Strategies
22 Tofacitinib Market, Conclusions And Recommendations
22.1 Conclusions
22.2 Recommendations
22.2.1 Product
22.2.2 Place
22.2.3 Price
22.2.4 Promotion
22.2.5 People
23 Appendix
23.1 Geographies Covered
23.2 Market Data Sources
23.3 Research Methodology
23.4 Currencies
23.5 The Business Research Company
23.6 Copyright and Disclaimer

ページTOPに戻る

Table of Contents

Summary

Tofacitinib Global Market Opportunities And Strategies To 2032 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global tofacitinib market as it emerges from the COVID-19 shut down.

Reasons to Purchase
• Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:
Where is the largest and fastest growing market for tofacitinib? How does the market relate to the overall economy, demography, and other similar markets? What forces will shape the market going forward? The tofacitinib market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider tofacitinib market; and compares it with other markets.

The report covers the following chapters.
• Introduction and Market Characteristics
Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by dosage strength, by indication and by distribution channel.
• Key Trends
Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Macro-Economic Scenario
The report provides an analysis of the impact of the Russia-Ukraine war, impact of the COVID-19 pandemic and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the tofacitinib market.
• Global Market Size and Growth
Global historic (2017-2022) and forecast (2022-2027, 2032F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis
Historic (2017-2022) and forecast (2022-2027, 2032F) market values and growth and market share comparison by region and country.
• Market Segmentation
Contains the market values (2017-2022) (2022-2027, 2032F) and analysis for each segment by drug class, by dosage strength, by indication and by distribution channel in the market. Historic (2017-2022) and forecast (2022-2027) and (2027-2032) market values and growth and market share comparison by region market.
• Regional Market Size and Growth
Regional market size (2022), historic (2017-2022) and forecast (2022-2027,2032F) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape
Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Key Mergers and Acquisitions
Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Market Opportunities And Strategies
Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations
This section includes recommendations for tofacitinib providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix
This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope
Markets Covered:
1) By Drug Class: Antirheumatic; Janus kinase inhibitor; Immunosuppressant
2) By Dosage Strength: 5mg; 10mg; 11mg; 22mg
3) By Indication: Ulcerative Colitis; Rheumatoid Arthritis; Psoriasis; Other Indications
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Companies Mentioned: Pfizer Inc; Beacon Pharmaceuticals PLC; Pharmascience Inc.; Qilu Pharmaceutical Co., Ltd; Delta Pharma Limited; Drug International Limited; Globe Group

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; tofacitinib indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

The Business Research Company　(TBRC)社の医薬分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

The Business Research Company　(TBRC)社はどのような調査会社ですか?

The Business Research Company (TBRC)はインドを主要拠点に世界の多様な市場を調査・予測し、調査レポートを積極的に出版しています。調査対象には技術、ライフサイエンス、重... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

2032年までのトファシチニブの世界市場機会と戦略

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

The Business Research Company (TBRC)社の医薬分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

The Business Research Company (TBRC)社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?

The Business Research Company　(TBRC)社の医薬分野での最新刊レポート

The Business Research Company　(TBRC)社はどのような調査会社ですか?